MYC and neuroblastoma: In conclusion, we have demonstrated the efficacy of CDK inhibitors in inhibiting neuroblastoma growth and metastasis in vivo, regardless of the MYC-N amplification status of the cells, thereby offering potential alternative therapeutic avenue compared to the commonly used ATRA.